Replies to post #900 on Ariad Pharmaceuticals Inc fka ARIA

[BTH]

they are not therapeutically equivalent

If all mTORs are of the same class and act on the same target, how does one have more efficacy over the other.

Is it simply a function of the dosing schedule, and dosing amount?

[BTH]

the cytostatic nature of many new therapies (e.g. antiangiogenic agents and mTOR inhibitors) may cause early effects in tumours that may not involve changes in tumour size and may consequently be missed by anatomical measurements [18]. Furthermore, a responding sarcoma may initially increase in physical size as a result of intratumoural haemorrhage or myxoid degeneration

This is somewhat concerning to me.

What if the investigators of the SUCCEED trial are mistakenly throwing out Ridaforolimus patients too quickly (even though, at a later point in time, the mTOR-inhibition will be so great, these tumors will eventually end up shrinking in a scan, despite the early stage "increase in physical size"?